ESR1 and breast neoplasm: The exclusive antagonistic activity exerted by MIBE on ERα- and GPER-mediated signaling as shown in the present study (Figure 8), could represent a promising pharmacological approach either at the beginning or during the progression of breast tumors which express one or both receptors.